TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32567984

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid 5% cream twice daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical tranexamic acid 5% cream plus intradermal injections of PRP every 3 weeks for 12 weeks
Number of subjects: 40
Study: 35632459

Group type: EXPERIMENTAL
Intervention: Intervention message targeting kin care
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Intervention message targeting disease avoidance
Number of subjects: 969

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 969
Study: 33427016

Group type: COMPARATOR
Intervention: delta-9-tetrahydrocannabinol (THC)
Number of subjects: 128
Study: 35221304

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adrenaline (0.01 mg/mL)
Number of subjects: 60
Study: 34176611

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Diabetes distress
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Double-mediation path through automatic negative thinking and diabetes distress
Number of subjects: 264
Study: 34125267

Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 35419636

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 33837162

Group type: EXPERIMENTAL
Intervention: IASTM
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Flossing
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both IASTM and flossing
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (nondominant shoulders)
Number of subjects: 80
Study: 33814268

Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Number of subjects: 44
Study: 36026542

Group type: EXPERIMENTAL
Intervention: Taylor-Scham approach
Number of subjects: 15

Group type: COMPARATOR
Intervention: FCU-Splitting approach
Number of subjects: 15
Study: 36517170

Group type: EXPERIMENTAL
Intervention: Early rhythm control
Number of subjects: 217

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study: 32920641

Group type: EXPERIMENTAL
Intervention: 5 doses of 4.5 x 10^5 PfSPZ (Days 1, 3, 5, and 7; Week 16)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 doses of 9.0 × 10^5 PfSPZ (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 doses of 18.0 × 10^5 PfSPZ (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 doses of 27.0 × 10^5 for dose 1 and 9.0 × 10^5 for doses 2 and 3 (Group 4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-boost (after 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 60
Study: 32336211

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic workout using a lower extremity cycle ergometer and a balance protocol once a week
Number of subjects: 14

Group type: COMPARATOR
Intervention: Balance protocol (Control Group)
Number of subjects: 14
Study: 35395930

Group type: EXPERIMENTAL
Intervention: Motivational information intervention
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Goal setting intervention
Number of subjects: 26
Study: 36258845

Group type: EXPERIMENTAL
Intervention: ERAS-based optimized analgesia measures
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional analgesia measures
Number of subjects: 120
Study: 32567654

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Practice group
Number of subjects: 68
Study: 32782111

Group type: EXPERIMENTAL
Intervention: Self-acupressure applied to the TH-6 acupuncture point for 15 min twice a day for one week
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 34406173

Group type: EXPERIMENTAL
Intervention: Linked-color imaging (LCI)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Blue-laser imaging (BLI)-bright
Number of subjects: 205

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: All groups (WLI, BLI-bright, LCI)
Number of subjects: 205
Study: 32053977

Group type: EXPERIMENTAL
Intervention: Breezing™
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular metabolism tracking
Number of subjects: 28
Study: 33853109

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (measured by electrodermal activity of auricular acupoints)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-assessment survey regarding interest in auriculotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-assessment survey regarding willingness to travel for treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of median current and average ranking of AAs
Number of subjects: 46
Study: 32072617

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 141

Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 141
Study: 32569127

Group type: EXPERIMENTAL
Intervention: Higher-volume resistance training (HV-RT, 6 sets per exercise)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lower-volume resistance training (LV-RT, 3 sets per exercise)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Higher-volume resistance training (HV-RT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lower-volume resistance training (LV-RT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CT, no exercise)
Number of subjects: 58
Study: 34507406

Group type: EXPERIMENTAL
Intervention: Cognitive dual task
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Motor dual task
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal walking speed with obstacle
Number of subjects: 64
Study: 35886043

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 4297
Study: 33242251

Group type: EXPERIMENTAL
Intervention: Hourly staircase sprint interval exercise (stair snacks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sedentary condition
Number of subjects: 10
Study: 32088934

Group type: EXPERIMENTAL
Intervention: WeChat social media platform as a patient reminder tool
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (no social media reminder)
Number of subjects: 222
Study: 35325684

Group type: EXPERIMENTAL
Intervention: Theta transcranial alternating current stimulation (tACS) at 5 Hz, 1 mA
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Posterior-anterior tACS
Number of subjects: 18
Study: 34746425

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg thrice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 35322080

Group type: EXPERIMENTAL
Intervention: Immersive VR training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional digit mobilization (CDM) training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-immersive VR training
Number of subjects: 54
Study: 34673691

Group type: EXPERIMENTAL
Intervention: Finerenone (Kerendia)
Number of subjects: 0
Study: 32622397

Group type: EXPERIMENTAL
Intervention: Thulium laser transurethral vaporesection of the prostate (ThuVARP)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 410
Study: 35642516

Group type: EXPERIMENTAL
Intervention: Active ptES + active iBT (double-active)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Active ptES + sham iBT (ptES-only)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sham ptES + sham iBT (double-sham)
Number of subjects: 210
Study: 32576287

Group type: EXPERIMENTAL
Intervention: Test preparation (Paracetamol/Orphenadrine combination)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference preparation (Paracetamol/Orphenadrine combination)
Number of subjects: 28
Study: 35184146

Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine gluconate (AQC)
Number of subjects: 199

Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol (ALC)
Number of subjects: 199
Study: 34337834

Group type: EXPERIMENTAL
Intervention: Projected extinctions of invasive‐threatened species
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive alien species (IAS) impact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Species composition shift
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological invasions
Number of subjects: 0
Study: 32747473

Group type: COMPARATOR
Intervention: Distance learning program consisting of 3 program modules with online tutorials, webinars, booster video vignettes, and individualized antibiotic prescribing feedback reports over 11 months.
Number of subjects: 29762

Group type: COMPARATOR
Intervention: Distance learning program
Number of subjects: 29762
Study: 35770697

Group type: EXPERIMENTAL
Intervention: Oral fluid‐based HIV self‐testing (HIVST)
Number of subjects: 32
Study: 33542175

Group type: EXPERIMENTAL
Intervention: Oral oxytocin (24IU)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 218
Study: 35509808

Group type: EXPERIMENTAL
Intervention: MyLifestyleCoach intervention
Number of subjects: 1142
Study: 33545094

Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac (Sputnik V) vaccine (0.5 mL/dose, prime-boost regimen with rAd26 and rAd5 vectors, administered intramuscularly with a 21-day interval)
Number of subjects: 21977

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21977

Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac (Sputnik V) vaccine
Number of subjects: 21977
Study: 34197941

Group type: EXPERIMENTAL
Intervention: Cluster randomization
Number of subjects: 40
Study: 32459426

Group type: EXPERIMENTAL
Intervention: Personalized feedback using digital step counters (pedometers)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 215
Study: 35183238

Group type: EXPERIMENTAL
Intervention: Storytelling-instructional-humor approach
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Storytelling-analogy approach
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: Storytelling-emotion-focused approach
Number of subjects: 24000

Group type: COMPARATOR
Intervention: No video (control group)
Number of subjects: 24000
Study: 33639662

Group type: EXPERIMENTAL
Intervention: Takespro HPV intervention (health education through videos and booklets for 6 months)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care from the school (control group)
Number of subjects: 128
Study: 36443882

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (ISTp) using ultra-sensitive malaria rapid diagnostic test (us-RDT) and pyronaridine-artesunate (Pyramax®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP)
Number of subjects: 0
Study: 34100082

Group type: EXPERIMENTAL
Intervention: Sequential mixed-nutrient meals
Number of subjects: 1002
Study: 32489146

Group type: EXPERIMENTAL
Intervention: letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) with Sorafenib (400 mg/bid daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) without Sorafenib
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: letrozole and cyclophosphamide with/without Sorafenib
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High responders (based on Ki67 variation)
Number of subjects: 90
Study: 37921933

Group type: EXPERIMENTAL
Intervention: Antegrade flexible ureteroscopy (FURS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 61
Study: 33495978

Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nutrition (NUT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Exercise plus Nutrition (EX+NUT)
Number of subjects: 48
Study: 32727474

Group type: EXPERIMENTAL
Intervention: Awareness of birth registration
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Mother's education
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Urban vs Rural residence
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Religion
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Possession of own birth certificate
Number of subjects: 383
Study: 32940568

Group type: EXPERIMENTAL
Intervention: Client-centered lifestyle intervention
Number of subjects: 0
Study: 34880372

Group type: EXPERIMENTAL
Intervention: 3% gelatin solution (30 ml/kg) in group A (n=21)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3% gelatin solution (15 ml/kg) in group B (n=21)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isotonic multi-electrolyte solution in control group C (n=22)
Number of subjects: 64
Study: 36135031

Group type: EXPERIMENTAL
Intervention: Supplementary strength program (3 sessions per week for 8 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no supplementary strength program)
Number of subjects: 21
Study: 34670228

Group type: EXPERIMENTAL
Intervention: 3-fraction stereotactic radiosurgery (SRS)
Number of subjects: 50
Study: 34419414

Group type: EXPERIMENTAL
Intervention: Riociguat (0.5 mg three times daily for 14 days, increased to 1.0 mg tid for the subsequent 14 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 32233007

Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted subcision (rSubcision)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional subcision
Number of subjects: 21
Study: 35289915

Group type: EXPERIMENTAL
Intervention: G-CSF prophylaxis with FOLFIRINOX
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: G-CSF prophylaxis with FOLFIRI/nab-paclitaxel
Number of subjects: 498

Group type: COMPARATOR
Intervention: Full dose-intensity (DI) in FOLFIRINOX group
Number of subjects: 498

Group type: COMPARATOR
Intervention: Full dose-intensity (DI) in FOLFIRI/nab-paclitaxel group
Number of subjects: 498
Study: 33879569

Group type: EXPERIMENTAL
Intervention: Extra-large high-density lipoproteins (XL.HDL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XL.HDL.FC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XL.HDL.C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein acetyls (GP)
Number of subjects: 0
Study: 35816900

Group type: EXPERIMENTAL
Intervention: Intermittent calorie restriction (100% of calorie needs on 5 days/week and 25% on 2 days/week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Daily calorie restriction (78% of calorie needs 7 days/week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control diet (100% of calorie needs 7 days/week)
Number of subjects: 36
Study: 33768223

Group type: EXPERIMENTAL
Intervention: Lachnosiraceae
Number of subjects: 492805

Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Number of subjects: 492805

Group type: EXPERIMENTAL
Intervention: Prausnitzii
Number of subjects: 492805
Study: 35742670

Group type: EXPERIMENTAL
Intervention: Exergames physical activity training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional physical activity training
Number of subjects: 48
Study: 32672329

Group type: EXPERIMENTAL
Intervention: Option Grids
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Shouldiscreen.com
Number of subjects: 237
Study: 32544560

Group type: EXPERIMENTAL
Intervention: Bimatoprost implant 10 μg
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Bimatoprost implant 15 μg
Number of subjects: 594

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 594
Study: 35025538

Group type: EXPERIMENTAL
Intervention: Lifestyle medicine intervention (LMG; n = 39; eight weekly sessions)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Waitlist control group (WLG; n = 40)
Number of subjects: 79
Study: 34823552

Group type: EXPERIMENTAL
Intervention: Reflective Fostering Programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 0
Study: 32716479

Group type: EXPERIMENTAL
Intervention: Continuous EEG (cEEG) for 30 to 48 hours
Number of subjects: 364

Group type: COMPARATOR
Intervention: Routine EEG (rEEG) - 2 sessions of 20 minutes each
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Continuous EEG (cEEG)
Number of subjects: 364
Study: 35384257

Group type: EXPERIMENTAL
Intervention: Topical probiotic-derived lotion
Number of subjects: 104

Group type: COMPARATOR
Intervention: 2.5% benzoyl peroxide
Number of subjects: 104
Study: 2012053242

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 240
Study: 36057827

Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (500μg methylcobalamin and 400μg folic acid once per day)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo tablets once per day
Number of subjects: 279
Study: 34033146

Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low-intensity exercise control (Buff Bones® [BB])
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: High-intensity resistance and impact training (HiRIT) with antiresorptive medication
Number of subjects: 115

Group type: COMPARATOR
Intervention: Low-intensity exercise control (Buff Bones® [BB]) with antiresorptive medication
Number of subjects: 115
Study: 33109643

Group type: EXPERIMENTAL
Intervention: CP@clinic (community paramedicine programme)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1461
Study: 35216547

Group type: EXPERIMENTAL
Intervention: Leuprorelin (3.75 mg s.c. monthly for the first 3 months followed by 11.25 mg s.c. every 3 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard of care (18 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 36
Study: 34618513

Group type: EXPERIMENTAL
Intervention: Higher alliance quality
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: More optimistic outcome expectation (OE)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Therapists’ self-perceived alliance-fostering effectiveness
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Cognitive–behavioral orientation
Number of subjects: 212
Study: 33744356

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 34623625

Group type: EXPERIMENTAL
Intervention: Vericiguat plus prior standard‐of‐care therapies (PSoCT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Prior standard‐of‐care therapies (PSoCT) alone
Number of subjects: 1000
Study: 32418145

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 50
Study: 36058604

Group type: EXPERIMENTAL
Intervention: Sexual harassment policy training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 32794567

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36102212

Group type: EXPERIMENTAL
Intervention: Acalabrutinib + Venetoclax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venetoclax + Obinutuzumab
Number of subjects: 0
Study: 32692358

Group type: EXPERIMENTAL
Intervention: (R)-α-lipoic acid (R-LA; 600 mg/d)
Number of subjects: 81
Study: 35324262

Group type: EXPERIMENTAL
Intervention: Health-focused Meatless Monday messages
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Environment-focused Meatless Monday messages
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 1244
Study: 33262411

Group type: EXPERIMENTAL
Intervention: Epi‐pledget
Number of subjects: 179

Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 179
Study: 35254011

Group type: EXPERIMENTAL
Intervention: Endocrown
Number of subjects: 40

Group type: COMPARATOR
Intervention: PCCR+post
Number of subjects: 40
Study: 33231701

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) intravitreal implant
Number of subjects: 324
Study: 33475684

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: gemcitabine/nab-paclitaxel
Number of subjects: 102
Study: 33157330

Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (aPDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive antibiotic gel therapy (aAGT) (metronidazole 400 mg and amoxicillin 500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical debridement (MD) alone
Number of subjects: 0
Study: 32928014

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2mls, 8 mg) intravenously
Number of subjects: 192

Group type: COMPARATOR
Intervention: Normal saline (placebo, 2mls) intravenously
Number of subjects: 192
Study: 32734750

Group type: EXPERIMENTAL
Intervention: Pilates exercise (3 sessions per week for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 32989532

Group type: EXPERIMENTAL
Intervention: Hot snare polypectomy (HSP)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 272
Study: 33084406

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment including hemoglobin and plasma retinol analysis
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Household food consumption and food insecurity assessment
Number of subjects: 168
Study: 35289921

Group type: EXPERIMENTAL
Intervention: PROSPER prevention delivery system implemented in middle schools
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 1985
Study: 34431178

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 115